Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer
cells. Biomed 101 may protect normal cells from the side effects of interleukin-2.
PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients
receiving interleukin-2 for kidney cancer.